SIG
XBI icon

Sargent Investment Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sargent Investment Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Buy
4,740
+70
+1% +$9.46K 0.09% 139
2026
Q1 		$596K Hold
4,670
– – 0.08% 148
2025
Q4 		$569K Buy
+4,670
New +$535K 0.07% 149
2025
Q3 		– Sell
-4,050
Closed -$349K – 235
2025
Q2 		$349K Sell
4,050
-80
-2% -$6.38K 0.05% 181
2025
Q1 		$335K Sell
4,130
-340
-8% -$30.4K 0.05% 179
2024
Q4 		$398K Sell
4,470
-180
-4% -$17.4K 0.07% 158
2024
Q3 		$459K Hold
4,650
– – 0.08% 127
2024
Q2 		$431K Buy
4,650
+450
+11% +$40.3K 0.09% 129
2024
Q1 		$399K Sell
4,200
-70
-2% -$6.5K 0.09% 130
2023
Q4 		$381K Sell
4,270
-530
-11% -$39.4K 0.08% 138
2023
Q3 		$350K Hold
4,800
– – 0.08% 143
2023
Q2 		$399K Hold
4,800
– – 0.1% 127
2023
Q1 		$370K Hold
4,800
– – 0.1% 130
2022
Q4 		$398K Sell
4,800
-600
-11% -$48.6K 0.12% 126
2022
Q3 		$446K Buy
5,400
+1,060
+24% +$89.4K 0.14% 113
2022
Q2 		$322K Buy
4,340
+250
+6% +$18.8K 0.1% 136
2022
Q1 		$368K Buy
4,090
+460
+13% +$42.5K 0.09% 135
2021
Q4 		$406K Buy
3,630
+90
+3% +$10.9K 0.09% 134
2021
Q3 		$445K Hold
3,540
– – 0.11% 127
2021
Q2 		$479K Hold
3,540
– – 0.11% 124
2021
Q1 		$480K Hold
3,540
– – 0.13% 120
2020
Q4 		$498K Hold
3,540
– – 0.16% 105
2020
Q3 		$394K Sell
3,540
-300
-8% -$33.6K 0.14% 111
2020
Q2 		$432K Buy
3,840
+225
+6% +$22.2K 0.16% 101
2020
Q1 		$280K Hold
3,615
– – 0.13% 111
2019
Q4 		$344K Hold
3,615
– – 0.13% 113
2019
Q3 		$276K Hold
3,615
– – 0.12% 116
2019
Q2 		$317K Hold
3,615
– – 0.14% 116
2019
Q1 		$327K Hold
3,615
– – 0.16% 103
2018
Q4 		$259K Buy
+3,615
New +$291K 0.16% 104

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Sargent Investment Group's XBI Position: Q2 2026 in Review

Sargent Investment Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1.5% in Q2 2026, buying an estimated $9.46K and bringing the position to 4,740 shares worth $750K. The position accounts for 0.09% of the portfolio, ranked #139.

Sargent Investment Group first reported a position in XBI in Q4 2018 and has held it in 30 quarters since. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Sargent Investment Group held 4,740 shares of State Street SPDR S&P Biotech ETF worth $750K as of Q2 2026.
  • Sargent Investment Group bought 70 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $9.46K.
  • State Street SPDR S&P Biotech ETF made up 0.09% of Sargent Investment Group's portfolio in Q2 2026, its #139 holding.
  • Sargent Investment Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 30 quarters since.
  • 934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Sargent Investment Group's 13F filing for Q2 2026, filed 11 Aug 2026.